BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1324 related articles for article (PubMed ID: 21245015)

  • 1. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
    Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
    Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration.
    Gao HM; Kotzbauer PT; Uryu K; Leight S; Trojanowski JQ; Lee VM
    J Neurosci; 2008 Jul; 28(30):7687-98. PubMed ID: 18650345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.
    Duffy MF; Collier TJ; Patterson JR; Kemp CJ; Luk KC; Tansey MG; Paumier KL; Kanaan NM; Fischer DL; Polinski NK; Barth OL; Howe JW; Vaikath NN; Majbour NK; El-Agnaf OMA; Sortwell CE
    J Neuroinflammation; 2018 May; 15(1):129. PubMed ID: 29716614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
    Castro-Sánchez S; García-Yagüe ÁJ; López-Royo T; Casarejos M; Lanciego JL; Lastres-Becker I
    Glia; 2018 Aug; 66(8):1752-1762. PubMed ID: 29624735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
    Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
    J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α-synuclein mouse model of Parkinson's disease.
    Rauschenberger L; Behnke J; Grotemeyer A; Knorr S; Volkmann J; Ip CW
    Neurobiol Dis; 2022 Sep; 171():105798. PubMed ID: 35750147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
    Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson's disease.
    George S; Rey NL; Tyson T; Esquibel C; Meyerdirk L; Schulz E; Pierce S; Burmeister AR; Madaj Z; Steiner JA; Escobar Galvis ML; Brundin L; Brundin P
    Mol Neurodegener; 2019 Aug; 14(1):34. PubMed ID: 31419995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
    Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
    Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minocycline inhibition of microglial rescues nigrostriatal dopaminergic neurodegeneration caused by mutant alpha-synuclein overexpression.
    Wang Y; Wang Q; Yu R; Zhang Q; Zhang Z; Li H; Ren C; Yang R; Niu H
    Aging (Albany NY); 2020 Jul; 12(14):14232-14243. PubMed ID: 32706757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid Induction of Dopaminergic Neuron Loss Accompanied by Lewy Body-Like Inclusions in A53T BAC-SNCA Transgenic Mice.
    Okuda S; Uemura N; Sawamura M; Taguchi T; Ikuno M; Uemura MT; Yamakado H; Takahashi R
    Neurotherapeutics; 2022 Jan; 19(1):289-304. PubMed ID: 34935120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys.
    Recasens A; Dehay B; Bové J; Carballo-Carbajal I; Dovero S; Pérez-Villalba A; Fernagut PO; Blesa J; Parent A; Perier C; Fariñas I; Obeso JA; Bezard E; Vila M
    Ann Neurol; 2014 Mar; 75(3):351-62. PubMed ID: 24243558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
    Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
    Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.
    Bourdenx M; Dovero S; Engeln M; Bido S; Bastide MF; Dutheil N; Vollenweider I; Baud L; Piron C; Grouthier V; Boraud T; Porras G; Li Q; Baekelandt V; Scheller D; Michel A; Fernagut PO; Georges F; Courtine G; Bezard E; Dehay B
    Acta Neuropathol Commun; 2015 Jul; 3():46. PubMed ID: 26205255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
    Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
    J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease.
    Liu Z; Qiu AW; Huang Y; Yang Y; Chen JN; Gu TT; Cao BB; Qiu YH; Peng YP
    Brain Behav Immun; 2019 Oct; 81():630-645. PubMed ID: 31351185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.
    Sharma N; Nehru B
    Mol Neurobiol; 2016 Jul; 53(5):3326-3337. PubMed ID: 26081143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor 4 stimulation with monophosphoryl lipid A ameliorates motor deficits and nigral neurodegeneration triggered by extraneuronal α-synucleinopathy.
    Venezia S; Refolo V; Polissidis A; Stefanis L; Wenning GK; Stefanova N
    Mol Neurodegener; 2017 Jul; 12(1):52. PubMed ID: 28676095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.